Showing results (31-40 of 143) with videos related to

Sort By:
Pageof 15
Gynecologic Oncology Reports|April 6, 2017
Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewHaller J Smith, J Michael Straughn, Donald J Buchsbaum, et al.
Obstetrics and Gynecology|June 2, 2007
Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinomaDavid E Cohn, Warner K Huh, Jeffrey M Fowler, et al.
American Journal of Obstetrics and Gynecology|May 16, 2003
A cost-effectiveness analysis of management strategies for cervical intraepithelial neoplasia grades 2 and 3Marc J Kleinberg, J Michael Straughn, Jeffery S A Stringer, et al.
Gynecologic Oncology|October 16, 2013
The Wnt/β-catenin pathway in ovarian cancer: a reviewRebecca C Arend, Angelina I Londoño-Joshi, J Michael Straughn, et al.
Gynecologic Oncology|January 31, 2021
Standing on the shoulders of giants: Mentorship advice from leaders in the fieldTeresa K L Boitano, Dennis S Chi, Larry J Copeland, et al.
World Journal of Stem Cells|September 27, 2014
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?Christen L Walters Haygood, Rebecca C Arend, J Michael Straughn, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 24, 2018
Predictors of Unplanned Reoperation for Ovarian Cancer Patients From the National Surgical Quality Improvement Program DatabaseMichael D Toboni, Haller J Smith, Sejong Bae, et al.
Abdominal Radiology (New York)|May 5, 2023
Short-term outcomes of uterine artery embolization for urgent or emergent abnormal uterine bleedingS Rodes Brown, Brandon Roane, Theresa M Caridi, et al.
Gynecologic Oncology Reports|September 29, 2025
Scholarly productivity during gynecologic oncology fellowship: A cross-sectional survey of graduates from 2020 to 2024Glenn P Boyles, Chelsey I Vranes, Leslie H Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysisDavid E Cohn, Kenneth H Kim, Kimberly E Resnick, et al.
Pageof 15